{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:38:51Z","timestamp":1793047131856,"version":"4.5.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T00:00:00Z","timestamp":1645401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T00:00:00Z","timestamp":1645401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["857722"],"award-info":[{"award-number":["857722"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["K23 DK129836"],"award-info":[{"award-number":["K23 DK129836"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Allergy Asthma Clin Immunol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Activated phosphoinositide 3-kinase (PI3K) \u03b4 syndrome (APDS) is a rare form of primary immunodeficiency with 243 known cases reported in the literature. Known findings associated with the condition include recurrent sinusitis and bronchitis, bronchiectasis, immune cytopenias, mild developmental delay, splenomegaly, and lymphadenopathy. We report the case of a child with APDS accompanied by unique clinical features: nephromegaly and growth hormone deficiency with associated pituitary anatomic abnormality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      The patient is a nine-year-old boy with a heterozygous de novo variant in\n                      <jats:italic>phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit \u03b4<\/jats:italic>\n                      (p.E1021K), previously reported in association with APDS. Our patient, who had no family history of immunodeficiency, exhibits classic findings of this syndrome but also has unique features that extend the phenotypic spectrum of this disorder. At 5\u00a0years of age, the patient showed marked growth deceleration and was demonstrated to have growth hormone (GH) deficiency with associated pituitary anatomic abnormality. He started GH therapy with an excellent response. He additionally has bilateral nephromegaly of unclear etiology, microscopic hematuria and proteinuria, asthma, and has developed left hip pain with arthrocentesis consistent with oligoarticular juvenile idiopathic arthritis. At age nine, the patient was referred to genetics and whole exome sequencing revealed APDS. Though there was initial concern that GH may increase risk for malignancy as GH signals through the PI3K pathway, he was allowed to continue treatment as the PI3K pathway was considered constitutively active at baseline.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our patient\u2019s unique presentation adds to the clinical information regarding APDS, demonstrates the utility of genetic testing and illustrates the importance of a multidisciplinary collaborative approach in managing this complex syndrome.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13223-022-00655-5","type":"journal-article","created":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T15:21:30Z","timestamp":1645456890000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Activated phosphoinositide 3-kinase \u03b4 syndrome associated with nephromegaly, growth hormone deficiency, bronchiectasis: a case report"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6384-9138","authenticated-orcid":false,"given":"Megan","family":"Craig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bob","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Wigby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan A.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Bakhoum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Naheedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateja","family":"Cernelc-Kohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,21]]},"reference":[{"key":"655_CR1","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12706","author":"M Elgizouli","year":"2016","unstructured":"Elgizouli M, Lowe DM, Speckmann C, et al. Activating PI3K\u03b4 mutations in a cohort of 669 patients with primary immunodeficiency. Clin Exp Immunol. 2016. https:\/\/doi.org\/10.1111\/cei.12706.","journal-title":"Clin Exp Immunol"},{"key":"655_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2771","author":"CL Lucas","year":"2014","unstructured":"Lucas CL, Kuehn HS, Zhao F, et al. Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110\u03b4 result in T cell senescence and human immunodeficiency. Nat Immunol. 2014. https:\/\/doi.org\/10.1038\/ni.2771.","journal-title":"Nat Immunol"},{"key":"655_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-019-08738-9","author":"M Jamee","year":"2020","unstructured":"Jamee M, Moniri S, Zaki-Dizaji M, et al. Clinical, immunological, and genetic features in patients with activated PI3K\u03b4 syndrome (APDS): a systematic review. Clin Rev Allergy Immunol. 2020. https:\/\/doi.org\/10.1007\/s12016-019-08738-9.","journal-title":"Clin Rev Allergy Immunol"},{"key":"655_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.06.021","author":"TI Coulter","year":"2017","unstructured":"Coulter TI, Chandra A, Bacon CM, et al. Clinical spectrum and features of activated phosphoinositide 3-kinase \u03b4 syndrome: a large patient cohort study. J Allergy Clin Immunol. 2017. https:\/\/doi.org\/10.1016\/j.jaci.2016.06.021.","journal-title":"J Allergy Clin Immunol"},{"key":"655_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00369","author":"D Michalovich","year":"2018","unstructured":"Michalovich D, Nejentsev S. Activated PI3 kinase delta syndrome: from genetics to therapy. Front Immunol. 2018. https:\/\/doi.org\/10.3389\/fimmu.2018.00369.","journal-title":"Front Immunol"},{"key":"655_CR6","doi-asserted-by":"publisher","DOI":"10.1126\/science.1243292","author":"I Angulo","year":"2013","unstructured":"Angulo I, Vadas O, Gar\u00e7on F, et al. Phosphoinositide 3-kinase \u03b4 gene mutation predisposes to respiratory infection and airway damage. Science. 2013. https:\/\/doi.org\/10.1126\/science.1243292.","journal-title":"Science"},{"key":"655_CR7","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20180010","author":"DT Avery","year":"2018","unstructured":"Avery DT, Kane A, Nguyen T, et al. Germline-activating mutations in PIK3CD compromise B cell development and function. J Exp Med. 2018. https:\/\/doi.org\/10.1084\/jem.20180010.","journal-title":"J Exp Med"},{"key":"655_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.04.041","author":"KS Lee","year":"2006","unstructured":"Lee KS, Park SJ, Kim SR, Min KH, Jin SM, Puri KD, et al. Phosphoinositide 3-kinase-delta inhibitor reduces vascular permeability in a murine model of asthma. J Allergy Clin Immunol. 2006. https:\/\/doi.org\/10.1016\/j.jaci.2006.04.041.","journal-title":"J Allergy Clin Immunol"},{"key":"655_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-016-0436-2","author":"T Southworth","year":"2016","unstructured":"Southworth T, Plumb J, Gupta V, Pearson J, Ramis I, Lehner MD, et al. Anti-inflammatory potential of PI3K\u03b4 and JAK inhibitors in asthma patients. Respir Res. 2016. https:\/\/doi.org\/10.1186\/s12931-016-0436-2.","journal-title":"Respir Res"},{"key":"655_CR10","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.2014.870155","author":"P Norman","year":"2014","unstructured":"Norman P. Evaluation of WO2013116562A, an orally active PI3K\u03b4 inhibitor for the treatment of asthma. Expert Opin Ther Pat. 2014. https:\/\/doi.org\/10.1517\/13543776.2014.870155.","journal-title":"Expert Opin Ther Pat"},{"key":"655_CR11","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000015329","author":"GM Li","year":"2019","unstructured":"Li GM, Liu HM, Guan WZ, Xu H, Wu BB, Feng JY, et al. A mutation in PIK3CD gene causing pediatric systemic lupus erythematosus: a case report. Medicine. 2019. https:\/\/doi.org\/10.1097\/MD.0000000000015329.","journal-title":"Medicine"},{"key":"655_CR12","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1400350","author":"A Su\u00e1rez-Fueyo","year":"2014","unstructured":"Su\u00e1rez-Fueyo A, Rojas JM, Cariaga AE, Garc\u00eda E, Steiner BH, Barber DF, et al. Inhibition of PI3K\u03b4 reduces kidney infiltration by macrophages and ameliorates systemic lupus in the mouse. J Immunol. 2014. https:\/\/doi.org\/10.4049\/jimmunol.1400350.","journal-title":"J Immunol"},{"key":"655_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2012.01.030","author":"B Bartok","year":"2012","unstructured":"Bartok B, Boyle DL, Liu Y, Ren P, Ball ST, Bugbee WD, et al. PI3 kinase \u03b4 is a key regulator of synoviocyte function in rheumatoid arthritis. Am J Pathol. 2012. https:\/\/doi.org\/10.1016\/j.ajpath.2012.01.030.","journal-title":"Am J Pathol"},{"key":"655_CR14","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1300950","author":"B Bartok","year":"2014","unstructured":"Bartok B, Hammaker D, Firestein GS. Phosphoinositide 3-kinase \u03b4 regulates migration and invasion of synoviocytes in rheumatoid arthritis. J Immunol. 2014. https:\/\/doi.org\/10.4049\/jimmunol.1300950.","journal-title":"J Immunol"},{"key":"655_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/pai.12585","author":"P Olbrich","year":"2016","unstructured":"Olbrich P, Lorenz M, Cura Daball P, Lucena JM, Rensing-Ehl A, Sanchez B, et al. Activated PI3K\u03b4 syndrome type 2: two patients, a novel mutation, and review of the literature. Pediatr Allergy Immunol. 2016. https:\/\/doi.org\/10.1111\/pai.12585.","journal-title":"Pediatr Allergy Immunol"},{"key":"655_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-020-00420-6","author":"M Ewertowska","year":"2020","unstructured":"Ewertowska M, Grze\u015bk E, Urba\u0144czyk A, D\u0105browska A, B\u0105bol-Pokora K, \u0141\u0119cka M, et al. Activated phosphoinositide 3-kinase delta syndrome 1 and 2 (APDS 1 and APDS 2): similarities and differences based on clinical presentation in two boys. Allergy Asthma Clin Immunol. 2020. https:\/\/doi.org\/10.1186\/s13223-020-00420-6.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"655_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-007-9025-5","author":"NJ Lanning","year":"2006","unstructured":"Lanning NJ, Carter-Su C. Recent advances in growth hormone signaling. Rev Endocr Metab Disord. 2006. https:\/\/doi.org\/10.1007\/s11154-007-9025-5.","journal-title":"Rev Endocr Metab Disord"}],"container-title":["Allergy, Asthma &amp; Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-022-00655-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13223-022-00655-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-022-00655-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T15:24:07Z","timestamp":1645457047000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacijournal.biomedcentral.com\/articles\/10.1186\/s13223-022-00655-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,21]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["655"],"URL":"https:\/\/doi.org\/10.1186\/s13223-022-00655-5","relation":{},"ISSN":["1710-1492"],"issn-type":[{"value":"1710-1492","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,21]]},"assertion":[{"value":"7 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The need for ethics approval was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patient\u2019s parent provided written consent for this publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Megan Craig, Mateja Cernelc-Kohan, Kristen Wigby, Susan A. Phillips, Christine Bakhoum, and John Naheedy have no competing interests to disclose. Bob Geng is a consultant for Pharming, Kedrion, and Koru. He is a speaker and consultant for Takeda and Grifols.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15"}}